Group 1 - The core revenue composition of Baiyang Pharmaceutical for the year 2024 is as follows: sales of pharmaceuticals and medical devices account for 92.5%, brand services account for 7.18%, and other businesses account for 0.32% [1] Group 2 - As of the announcement date, Baiyang Pharmaceutical Group has pledged approximately 146 million shares, representing 39.49% of its total holdings [3] - Beijing Baiyang Chengchuang Pharmaceutical Investment Co., Ltd. has pledged 9.98 million shares, which is 49.9% of its holdings [3] - Tianjin Huitong Asset Management Partnership has pledged 2.8 million shares, accounting for 48.86% of its holdings [3] - Tianjin Haohui Asset Management Partnership has pledged 2.1 million shares, representing 48.36% of its holdings [3] - Tianjin Huizhong Asset Management Partnership has pledged 2.1 million shares, which is 48.79% of its holdings [3] - Tianjin Huitong Asset Management Partnership has pledged 1.6 million shares, accounting for 48.93% of its holdings [3]
百洋医药：百洋医药集团有限公司累计质押股数约为1.46亿股